Physician profile
William K Armstrong
NPI 1902133424
$1,737.46
in general payments reported to CMS, 2019-2025
30 companies · $300 in 2025
The $300 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $213 · 2020: $130 · 2021: $229 · 2022: $205 · 2023: $368 · 2024: $293 · 2025: $300.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $961.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $961.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $229.73 | 2019-2025 | |
| Amgen INC. | $183.88 | 2019-2025 | Otezla, Repatha, Repatha |
| Novo Nordisk INC | $138.40 | 2019-2025 | Ozempic, Rybelsus |
| Abbvie INC. | $125.26 | 2021-2025 | |
| Astellas Pharma US INC | $106.38 | 2019-2024 | Veozah, Myrbetriq |
| Lilly USA, LLC | $105.95 | 2023-2025 | Mounjaro, Zepbound, Trulicity |
| Glaxosmithkline, LLC. | $101.66 | 2022-2025 | Shingrix, Arexvy, Bexsero |
| Abbott Laboratories | $98.45 | 2023-2024 | Freestyle Libre 3, Eterna |
| Merck Sharp & Dohme LLC | $87.68 | 2019-2021 | |
| Hologic Sales and Service, LLC | $56.77 | 2019-2023 | Aptima |
| Gilead Sciences, INC. | $48.88 | 2019-2020 | |
| Biohaven Pharmaceutical Holding Company LTD. | $47.41 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $38.66 | 2023 | Farxiga, Breztri |
| Esperion Therapeutics, INC. | $35.81 | 2021-2025 | Nexletol |
| Exact Sciences Corporation | $28.07 | 2023 | Cologuard Collection Kit |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inari Medical, INC. | $28.01 | 2024 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Otsuka America Pharmaceutical, INC. | $26.47 | 2024 | Rexulti |
| Viiv Healthcare Company | $25.93 | 2022 | |
| Sanofi-Aventis U.S. LLC | $24.98 | 2025 | |
| Exeltis, USA INC. | $24.58 | 2023 | Slynd |
| Sumitomo Pharma America, INC. | $22.75 | 2025 | Gemtesa |
| Allergan, INC. | $20.18 | 2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $20.00 | 2021 | |
| Medtronic USA, INC. | $18.91 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $17.47 | 2019 | |
| Bausch Health US, LLC | $17.22 | 2021 | |
| Edwards Lifesciences Corporation | $17.08 | 2023 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Eisai INC. | $13.98 | 2020 | |
| Agile Therapeutics, INC. | $13.84 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.07 | 2023 | Jardiance, Tradjenta |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Armstrong listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.